Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cash & Equivalents (2019 - 2023)

Historic Cash & Equivalents for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $310.4 million.

  • ADC Therapeutics' Cash & Equivalents fell 1849.84% to $310.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $310.4 million, marking a year-over-year decrease of 1849.84%. This contributed to the annual value of $466544.0 for FY2022, which is 9989.84% down from last year.
  • As of Q3 2023, ADC Therapeutics' Cash & Equivalents stood at $310.4 million, which was down 1849.84% from $347.51 recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Cash & Equivalents registered a high of $439.2 billion during Q1 2021, and its lowest value of $115.55 during Q1 2020.
  • Over the past 5 years, ADC Therapeutics' median Cash & Equivalents value was $466544.0 (recorded in 2022), while the average stood at $26.0 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 38008758027576.48% in 2021, then tumbled by 9999.99% in 2022.
  • Over the past 5 years, ADC Therapeutics' Cash & Equivalents (Quarter) stood at $115.6 million in 2019, then tumbled by 99.57% to $494416.0 in 2020, then skyrocketed by 92754.75% to $459.1 million in 2021, then dropped by 28.89% to $326.4 million in 2022, then fell by 4.91% to $310.4 million in 2023.
  • Its last three reported values are $310.4 million in Q3 2023, $347.51 for Q2 2023, and $326441.0 during Q1 2023.